UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 232

Sortiert nach

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog

Advances in Hematology, 2013, Vol.2013, p.309637-11

2013

Volltextzugriff (PDF)

Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma

Advances in Hematology, 2014, Vol.2014 (2014), p.512508-6

2014

Volltextzugriff (PDF)

Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans

Advances in Hematology, 2013, Vol.2013, p.901589-5

2013

Volltextzugriff (PDF)

β-Thalassaemia Major in a Spanish Patient due to a Compound Heterozygosity for CD39 C→T/−28 A→C

Advances in hematology, 2009, Vol.2009, p.476342-3

2009

Volltextzugriff (PDF)

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

The lancet oncology, 2011-09, Vol.12 (9), p.841-851

2011

Volltextzugriff (PDF)

Chronic myeloid leukemia: reminiscences and dreams

Haematologica (Roma), 2016-05, Vol.101 (5), p.541

2016

Volltextzugriff (PDF)

Monitoring treatment of chronic myeloid leukemia

Haematologica (Roma), 2008-02, Vol.93 (2), p.161-169

2008

Volltextzugriff (PDF)

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

Haematologica (Roma), 2013-02, Vol.98 (2), p.193-200

2013

Volltextzugriff (PDF)

Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

The New England journal of medicine, 2005-01, Vol.352 (3), p.254-266

2005

Volltextzugriff (PDF)

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

The New England journal of medicine, 2006-12, Vol.355 (23), p.2408-2417

2006

Volltextzugriff (PDF)

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Haematologica (Roma), 2007-03, Vol.92 (3), p.401-404

2007

Volltextzugriff (PDF)

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

The New England journal of medicine, 2010-06, Vol.362 (24), p.2251-2259

2010

Volltextzugriff (PDF)

Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy

Bone marrow transplantation (Basingstoke), 2015-02, Vol.50 (2), p.282-288

2015

Volltextzugriff (PDF)

The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice

Haematologica (Roma), 2014-06, Vol.99 (6), p.1016

2014

Volltextzugriff (PDF)

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

Haematologica (Roma), 2008-06, Vol.93 (6), p.921-924

2008

Volltextzugriff (PDF)

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Blood, 2022-11, Vol.140 (Supplement 1), p.195-197

2022

Volltextzugriff (PDF)

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Haematologica (Roma), 2014-07, Vol.99 (7), p.1204

2014

Volltextzugriff (PDF)

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

Haematologica (Roma), 2012-06, Vol.97 (6), p.907-914

2012

Volltextzugriff (PDF)

Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib

Clinical chemistry (Baltimore, Md.), 2004-07, Vol.50 (7), p.1205-1213

2004

Volltextzugriff (PDF)

1 – 25 von 232

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(220)
Mit Volltextzugriff
(187)

Publikationsform

Artikel
(232)

Sprache

Englisch
(232)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Humans
(195)
Science & Technology
(182)
Life Sciences & Biomedicine
(179)
Hematology
(124)
Biological And Medical Sciences
(121)
Medical Sciences
(118)
Hematologic And Hematopoietic Diseases
(88)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(81)
Male
(78)
Female
(77)
Adult
(74)
Middle Aged
(70)
Oncology
(56)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Genetics
(46)
Aged
(43)
Polymerase Chain Reaction
(38)
Adolescent
(37)
Imatinib Mesylate
(31)
Fusion Proteins, Bcr-Abl - Genetics
(29)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog

Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma

Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans

β-Thalassaemia Major in a Spanish Patient due to a Compound Heterozygosity for CD39 C→T/−28 A→C

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Chronic myeloid leukemia: reminiscences and dreams

Monitoring treatment of chronic myeloid leukemia

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome

ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy

The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib

A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol

Suchergebnisse filtern